Versant Venture Management, LLC reported 8 positions worth $162.61M for the quarter ended Jun 30, 2026, up 15.0% on the prior quarter. It opened 0 new positions, added to 0, trimmed 1 and exited 0. Its largest holding is Monte Rosa Therapeutics, Inc. at 47.3% of the portfolio.
Reported 13F market value at each quarter end. A change mixes trading with price moves in the positions held.
Dollar value of shares bought and sold each quarter, at that quarter’s price. It counts trading only, not price changes.
How many positions were opened, added to, trimmed or closed each quarter.
Share of reported value in each sector at every quarter end.
No positions were added to this quarter.
| Holding | Change | Change % | Trade Value | Weight |
|---|---|---|---|---|
| JBIO Jade Biosciences, Inc. | -534.0K | -35.0% | $11.87M | 13.55% |
No new positions this quarter.
No positions were closed this quarter.
| # | Activity | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| 1 | GLUE Monte Rosa Therapeutics, Inc. | Healthcare | 3.18M | $76.97M | 47.34% | 0 | 0.0% | Unchanged | 3.13% |
| 2 | IPSC Century Therapeutics, Inc. | Healthcare | 12.17M | $29.81M | 18.33% | 0 | 0.0% | Unchanged | 5.91% |
| 3 | JBIO Jade Biosciences, Inc. | Healthcare | 991.8K | $22.04M | 13.55% | -534.0K | -35.0% | Reduced | 1.56% |
| 4 | LENZ LENZ Therapeutics, Inc. | Healthcare | 2.66M | $15.09M | 9.28% | 0 | 0.0% | Unchanged | 8.46% |
| 5 | CTNM Contineum Therapeutics, Inc. | Healthcare | 542.6K | $8.89M | 5.47% | 0 | 0.0% | Unchanged | 1.65% |
| 6 | CRSP CRISPR Therapeutics AG | Healthcare | 148.8K | $8.12M | 4.99% | 0 | 0.0% | Unchanged | 0.15% |
| 7 | SKYE Skye Bioscience, Inc. | Healthcare | 251.0K | $1.39M | 0.856% | 0 | 0.0% | Unchanged | 5.06% |
| 8 | TPST Tempest Therapeutics, Inc. | Healthcare | 269.8K | $299.45K | 0.184% | 0 | 0.0% | Unchanged | 1.69% |
Tip. Select a row to see that position’s full history at Versant Venture Management.
As of its Q2 2026 13F filing, Versant Venture Management, LLC’s five largest positions were Monte Rosa Therapeutics, Inc. (GLUE) at 47.3%, Century Therapeutics, Inc. (IPSC) at 18.3%, Jade Biosciences, Inc. (JBIO) at 13.6%, LENZ Therapeutics, Inc. (LENZ) at 9.3%, Contineum Therapeutics, Inc. (CTNM) at 5.5% of the reported portfolio.
Versant Venture Management, LLC reported a 13F portfolio worth $162.61M across 8 positions for Q2 2026. That is up 15.0% from the previous quarter.
Its largest sales by value were Jade Biosciences, Inc. ($11.87M). It exited 0 positions entirely.
From the Form 13F-HR reports Versant Venture Management, LLC files with the SEC each quarter, within 45 days of quarter end. A 13F lists long positions in US-listed equities and options; it excludes short positions, cash, bonds and most non-US holdings.
13F data reflects long positions in US-listed equities and options as reported to the SEC up to 45 days after quarter end. It excludes short positions, cash, bonds and most non-US securities, so it is not a complete picture of a manager’s assets.